ADVERSE O
REACTIONS O
Side O
effects O
most O
commonly O
reported O
were O
drowsiness B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
and O
ataxia B-OSE_Labeled_AE
. O

The O
following O
have O
also O
been O
reported O
: O
Central O
Nervous O
System O
: O
confusion B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
slurred B-OSE_Labeled_AE
speech I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
Gastrointestinal O
System O
: O
constipation B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
Special O
Senses O
: O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
Cardiovascular O
System O
: O
hypotension B-OSE_Labeled_AE
Psychiatric O
and O
Paradoxical O
Reactions O
: O
stimulation B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
hyperexcited I-OSE_Labeled_AE
states I-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
rage B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
psychoses B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
spasticity I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
, O
and O
nightmares B-OSE_Labeled_AE
. O

Inappropriate B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
and O
other O
adverse B-OSE_Labeled_AE
behavioral I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
have O
been O
reported O
when O
using O
benzodiazepines O
. O

Should O
these O
occur O
, O
use O
of O
the O
drug O
should O
be O
discontinued O
. O

They O
are O
more O
likely O
to O
occur O
in O
children O
and O
in O
the O
elderly O
. O

Urogenital O
System O
: O
incontinence B-OSE_Labeled_AE
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
Skin O
and O
Appendages O
: O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
Laboratories O
: O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
and O
alkaline O
phosphatase O
Other O
: O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
including O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
hypersalivation B-OSE_Labeled_AE
Antegrade B-OSE_Labeled_AE
amnesia I-OSE_Labeled_AE
may O
occur O
using O
therapeutic O
dosages O
, O
the O
risk O
increasing O
at O
higher O
dosages O
. O

Amnestic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
may O
be O
associated O
with O
inappropriate B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
. O

Minor O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
EEG I-OSE_Labeled_AE
patterns O
, O
usually O
low-voltage O
fast O
activity O
, O
have O
been O
observed O
in O
patients O
during O
and O
after O
Valium O
therapy O
and O
are O
of O
no O
known O
significance O
. O

Because O
of O
isolated O
reports O
of O
neutropenia B-OSE_Labeled_AE
and O
jaundice B-OSE_Labeled_AE
, O
periodic O
blood O
counts O
and O
liver O
function O
tests O
are O
advisable O
during O
long-term O
therapy O
. O

Postmarketing O
Experience O
Injury O
, O
Poisoning O
and O
Procedural O
Complications O
There O
have O
been O
reports O
of O
falls B-OSE_Labeled_AE
and O
fractures B-OSE_Labeled_AE
in O
benzodiazepine O
users O
. O

The O
risk O
is O
increased O
in O
those O
taking O
concomitant O
sedatives O
( O
including O
alcohol O
) O
, O
and O
in O
the O
elderly O
. O

